Nature Medicine
August 6, 2026
James Rucker, Tim Mantingh, Jess Kerr-Gaffney et al.
1 citation
Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health...
Open MIND
July 9, 2026
Luke Baxter
Using serum samples collected from the PsiDeR trial—a randomised, double‑blind, placebo‑controlled study of a single 25 mg dose of psilocybin for treatment‑resistant depression (protocol: BMJ Open 2021;11:e056091)—we will investigate whether inflammatory marker trajectories and baseline inflammatory status are associated with antidepressant response at week 3 (endpoint). The inflammatory...
British Journal of Pharmacology
October 28, 2024
Laith Alexander, Dasha Anderson, Luke Baxter et al.
11 citations
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid-acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood. For example, key questions such as whether antidepressant and psychedelic effects involve related or independent...
Journal of psychopharmacology (Oxford, England)
August 1, 2024
Luke Baxter, Cheneal Puljević, Tim Piatkowski et al.
3 citations
The recreational use of LSD, a synthetic psychedelic drug, has surged in recent years, coinciding with a renewed research focus on its potential psychotherapeutic properties. This study aims to describe the experiences and perceptions of individuals engaging in LSD use for the first time, derived from a large international sample. This study utilised 2018 Global Drug Survey data collected from...
World Psychiatry
January 14, 2023
Oliver Howes, Luke Baxter
16 citations
The US Food and Drug Administration (FDA) approved 12 new drugs in psychiatry during the decade 2011-2021 (www.fda.gov/drugs/drug-approvals-and-databases). In comparison, it approved 50 new drugs in neurology and 135 in oncology over the same period. The FDA designated two new drugs as first-in-class in psychiatry (lofexidine and brexanolone) in the most recent reviewed period (2015-2021),...